Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics Plc ADR (NQ: AUTL ) 3.750 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Autolus Therapeutics Plc ADR < Previous 1 2 3 4 5 6 Next > Where Autolus Therapeutics Stands With Analysts June 02, 2023 Via Benzinga Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO June 02, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL May 22, 2023 From Autolus Therapeutics plc Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session May 15, 2023 Via Benzinga Preview: Autolus Therapeutics's Earnings May 03, 2023 Via Benzinga The Latest Analyst Ratings for Autolus Therapeutics April 28, 2023 Via Benzinga Earnings Outlook For Autolus Therapeutics March 06, 2023 Via Benzinga Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 15, 2023 Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. Via Benzinga Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA May 12, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress May 04, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO April 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner April 27, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids April 26, 2023 - Expanding the Autolus toolkit of T-cell engineering modules against complex and immunologically hostile cancers, including solid cancer applications From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting April 26, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Host Virtual Capital Markets Day April 25, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 April 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Publication in Molecular Therapy April 04, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces resignation of Chief Financial Officer March 14, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank March 13, 2023 From Autolus Therapeutics plc Via GlobeNewswire Tesla To Rally More Than 12%? Here Are 10 Other Analyst Forecasts For Wednesday March 08, 2023 HC Wainwright & Co. cut the price target for DURECT Corporation (NASDAQ: DRRX) from $35 to $32. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. DURECT shares fell 1.3% to close at $4.75 on... Via Benzinga Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress March 07, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023 February 15, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics announces Board changes January 20, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease January 09, 2023 From Autolus Therapeutics plc Via GlobeNewswire Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs December 21, 2022 From Autolus Therapeutics plc Via GlobeNewswire Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022 December 12, 2022 From Autolus Therapeutics plc Via GlobeNewswire Dow Tumbles 100 Points; Silver Rises Over 2% December 09, 2022 U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday Via Benzinga Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session December 09, 2022 Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate. Via Benzinga US Stocks Turn Higher; Nasdaq Rises 40 Points December 09, 2022 U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session December 09, 2022 Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.